Adagene to start Phase 1 study of ADG138 in Q4 2026
Adagene said it will begin a Phase 1 study of ADG138 for advanced solid tumors in Q4 2026.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Adagene gets NMPA IND clearance for ADG138
Adagene received NMPA clearance for the IND of ADG138, a double-masked HER2×CD3 T-cell engager, with a Phase 1 study in advanced solid tumors expected to start in China in Q4 2026.